Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.

Mori M, Ohashi T, Onizuka Y, Hiramatsu K, Hase M, Yun J, Matta A, Torii S.

Mult Scler J Exp Transl Clin. 2019 Jun 10;5(2):2055217319852727. doi: 10.1177/2055217319852727. eCollection 2019 Apr-Jun.

2.
3.

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study).

Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Yamanaka H, Takasaki Y, Mimori T, Hiramatsu K, Komatsu S, Tanaka Y.

Rheumatol Ther. 2016 Jun;3(1):129-141. doi: 10.1007/s40744-015-0023-x. Epub 2015 Dec 22.

4.

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.

Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Hiramatsu K, Takeuchi T.

RMD Open. 2016 Feb 18;2(1):e000189. doi: 10.1136/rmdopen-2015-000189. eCollection 2016.

5.

Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study.

Kario K, Saito I, Kushiro T, Teramukai S, Mori Y, Hiramatsu K, Kobayashi F, Shimada K.

J Clin Hypertens (Greenwich). 2013 Aug;15(8):555-61. doi: 10.1111/jch.12132. Epub 2013 May 31.

6.

Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis.

Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Mori Y, Okuda Y, Hiramatsu K; OMEGA Study Group.

Clin Exp Hypertens. 2014;36(4):236-43. doi: 10.3109/10641963.2013.810226. Epub 2013 Jul 18.

PMID:
23865387
7.

Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.

Kario K, Uehara Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K, Komiya M, Shimada K.

Drugs R D. 2013 Mar;13(1):75-85. doi: 10.1007/s40268-013-0007-7.

8.

Inhibitory effects of azelnidipine tablets on morning hypertension.

Kario K, Sato Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K, Komiya M, Shimada K.

Drugs R D. 2013 Mar;13(1):63-73. doi: 10.1007/s40268-013-0006-8.

9.
10.

Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study.

Saito I, Kario K, Kushiro T, Teramukai S, Zenimura N, Hiramatsu K, Kobayashi F, Shimada K.

Hypertens Res. 2013 Feb;36(2):177-82. doi: 10.1038/hr.2012.160. Epub 2012 Oct 25.

11.

Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study.

Teramoto T, Kawamori R, Miyazaki S, Teramukai S, Shirayama M, Hiramatsu K, Kobayashi F; OMEGA Study Group.

Hypertens Res. 2012 Dec;35(12):1136-44. doi: 10.1038/hr.2012.93. Epub 2012 Jul 5. Erratum in: Hypertens Res. 2012 Dec;35(12):1203.

12.

Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.

Saito I, Kushiro T, Zenimura N, Matsushita Y, Sagawa K, Hiramatsu K, Yamaguchi F.

J Nephrol. 2012 Sep-Oct;25(5):699-708. doi: 10.5301/jn.5000043.

PMID:
22020401
13.

Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a long-term special survey.

Iizuka T, Nishikawa Y, Mori Y, Zenimura N, Matsumoto T, Hiramatsu K, Komiya M.

Drugs R D. 2011;11(2):191-205. doi: 10.2165/11592460-000000000-00000.

14.

Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.

Mori Y, Nishikawa Y, Iizuka T, Zenimura N, Matsumoto T, Hiramatsu K, Komiya M.

Drugs R D. 2011;11(2):171-90. doi: 10.2165/11592450-000000000-00000.

16.

Estimating antihypertensive effects of combination therapy in an observational study using marginal structural models.

Sugihara M, Kushiro T, Saito I, Matsushita Y, Hiramatsu K.

Biom J. 2009 Oct;51(5):789-800. doi: 10.1002/bimj.200900025.

PMID:
19827055
17.

Blood pressure-lowering effects of angiotensin receptor antagonist monotherapy and in combination with other anti-hypertensive drugs in primary care settings in Japan.

Kushiro T, Saito I, Hirata K, Ishikawa M, Yamashita T, Matsushita Y, Sagawa K, Hiramatsu K, Komiya M.

Clin Exp Hypertens. 2009 Apr;31(2):127-41. doi: 10.1080/10641960802621275.

PMID:
19330602
18.

Influence of guidelines on physicians' assessment of blood pressure lowering effects and achievement rate of blood pressure target during transitional period of guidelines.

Kushiro T, Saito I, Sato Y, Hirata K, Kobayashi F, Sagawa K, Hiramatsu K, Komiya M.

Clin Exp Hypertens. 2009 Apr;31(2):116-26. doi: 10.1080/10641960802627348.

PMID:
19330601
19.

Early antihypertensive efficacy of olmesartan medoxomil.

Saito I, Kushiro T, Ishikawa M, Matsushita Y, Sagawa K, Hiramatsu K, Komiya M.

J Clin Hypertens (Greenwich). 2008 Dec;10(12):930-5. doi: 10.1111/j.1751-7176.2008.00050.x.

20.

The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan.

Saito I, Kushiro T, Hirata K, Sato Y, Kobayashi F, Sagawa K, Hiramatsu K, Komiya M.

J Clin Hypertens (Greenwich). 2008 Apr;10(4):272-9.

Supplemental Content

Loading ...
Support Center